908 Devices Inc. (NASDAQ:MASS) Director Buys $24,945.25 in Stock

908 Devices Inc. (NASDAQ:MASSGet Rating) Director Mark Spoto purchased 2,585 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was bought at an average cost of $9.65 per share, for a total transaction of $24,945.25. Following the completion of the acquisition, the director now directly owns 40,423 shares of the company’s stock, valued at $390,081.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

908 Devices Stock Up 5.4 %

908 Devices stock traded up $0.52 during midday trading on Thursday, hitting $10.10. The stock had a trading volume of 165,026 shares, compared to its average volume of 433,532. The company has a current ratio of 11.73, a quick ratio of 11.12 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average price of $14.75 and a 200 day moving average price of $16.99. 908 Devices Inc. has a 12 month low of $9.27 and a 12 month high of $28.45. The stock has a market cap of $319.06 million, a P/E ratio of -11.48 and a beta of 0.47.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in MASS. Fred Alger Management LLC lifted its stake in 908 Devices by 223.2% during the third quarter. Fred Alger Management LLC now owns 3,459,103 shares of the company’s stock worth $56,902,000 after purchasing an additional 2,388,844 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of 908 Devices by 25.5% during the third quarter. Vanguard Group Inc. now owns 1,422,151 shares of the company’s stock worth $23,394,000 after purchasing an additional 288,923 shares during the period. Lord Abbett & CO. LLC acquired a new stake in shares of 908 Devices during the third quarter worth $4,061,000. Nicholas Investment Partners LP lifted its position in shares of 908 Devices by 78.4% in the 1st quarter. Nicholas Investment Partners LP now owns 552,801 shares of the company’s stock worth $10,509,000 after buying an additional 242,968 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its holdings in shares of 908 Devices by 14.5% in the 3rd quarter. Eventide Asset Management LLC now owns 1,715,801 shares of the company’s stock valued at $28,225,000 after buying an additional 217,700 shares during the period. Institutional investors and hedge funds own 65.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, SVB Leerink dropped their target price on shares of 908 Devices from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, November 15th.

908 Devices Company Profile

(Get Rating)

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis.

See Also

Insider Buying and Selling by Quarter for 908 Devices (NASDAQ:MASS)

Receive News & Ratings for 908 Devices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 908 Devices and related companies with MarketBeat.com's FREE daily email newsletter.